Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

207.34 +2.88 (+1.41%)
Streaming Delayed Price Updated: 2:37 PM EST, Dec 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories Intl

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
9 Analysts Have This to Say About Charles River
Via Benzinga
Investing in the Aging Population: 3 Healthcare Stocks to Watch
America is becoming a much older country on average. These three healthcare stocks are ideally positioned for this demographic shift. 
Via InvestorPlace
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Evercore ISI Investor Conference
From Charles River Laboratories International, Inc.
Via Business Wire
The 3 Most Undervalued Tech Stocks to Buy Now: November 2023
Growth stocks are rallying but there are still bargains to be found. These three top tech picks can reward long-term investors. 
Via InvestorPlace
Expert Ratings for Charles River
Via Benzinga
8 Analysts Have This to Say About Charles River
Via Benzinga
What 5 Analyst Ratings Have To Say About Charles River
Via Benzinga
Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Labs Q3 Revenue Jumps 4% Despite Softer Client Spending, Narrows Outlook
Charles River Laboratories International Inc (NYSE: CRL) reported third-quarter (Q3) sales of $1.03 billion, an increase of 3.8% Y/Y, beating the  
Via Benzinga
Charles River Laboratories Announces Third-Quarter 2023 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches Real-Time Research Model Ordering, Introducing an Important Digital Innovation to Research Models & Services Business
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Third-Quarter 2023 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Provides Access to Relevant, Well-Characterized Pediatric PDX Collection for Oncology Research
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Achieves 90% Renewable Electricity Globally, Announces Progress on Environmental Goals
From Charles River Laboratories International, Inc.
Via Business Wire
Q4 Stock Predictions: 3 S&P 500 Stocks Ready to Soar
S&P 500 stocks are sliding amid a worrying interest rate environment. However, these three can buck the current downtrend. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Announces Opening of RightSourceSM Laboratory, Supporting Stevenage Biocluster
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL) Long Term Investor Alert: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 09/22/2023 -- Certain directors of Charles River Laboratories International, Inc are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. 
Via Benzinga
Charles River Laboratories to Host Virtual Investor Day
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Steer Clear of Outrageously Valued VinFast Stock. 3 EV Stocks to Buy Instead.
VinFast stock has gotten inflated since its blank-check merger in early August. Check out these three EV stocks instead. 
Via InvestorPlace
Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods
From Charles River Laboratories International, Inc.
Via Business Wire
WeWork's Journey From $47B Valuation To Possible Bankruptcy, Mastercard and Visa Reassess Ties with Binance Card, Hawaiian Electric Accused Of Jeopardizing Investigation Of Maui Wildfires: Today's Top Stories
Wall Street Journal 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Endangered Horseshoe Crabs Vital In Medical Research, Charles River Lab Commits To Enhanced Protection
Charles River Laboratories International Inc (NYSE: CRL) has joined hands with four significant entities in a pioneering move to amplify protections for the horseshoe crabs and the red knots bird... 
Via Benzinga
Charles River Laboratories Announces Plasmid Manufacturing Collaboration with Fondazione Telethon
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.